These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 22993451)

  • 1. Dopamine agonist withdrawal syndrome (DAWS): perils of flicking the dopamine 'switch'.
    Edwards MJ
    J Neurol Neurosurg Psychiatry; 2013 Feb; 84(2):120. PubMed ID: 22993451
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic.
    Pondal M; Marras C; Miyasaki J; Moro E; Armstrong MJ; Strafella AP; Shah BB; Fox S; Prashanth LK; Phielipp N; Lang AE
    J Neurol Neurosurg Psychiatry; 2013 Feb; 84(2):130-5. PubMed ID: 22933817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine agonist withdrawal syndrome: A comprehensive review.
    Yu XX; Fernandez HH
    J Neurol Sci; 2017 Mar; 374():53-55. PubMed ID: 28104232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suicide attempt in a dopamine agonist withdrawal syndrome in Parkinson's disease.
    Espindola M; Rojas NG; Vaisentein G; Da Prat G; Cesarini M; Etcheverry JL; Gatto EM
    Parkinsonism Relat Disord; 2024 Apr; 121():106017. PubMed ID: 38401377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Man With Persistent Dopamine Agonist Withdrawal Syndrome After 7 Years Being Off Dopamine Agonists.
    Huynh NT; Sid-Otmane L; Panisset M; Huot P
    Can J Neurol Sci; 2016 Nov; 43(6):859-860. PubMed ID: 26842385
    [No Abstract]   [Full Text] [Related]  

  • 6. Dopamine agonist withdrawal syndrome: implications for patient care.
    Nirenberg MJ
    Drugs Aging; 2013 Aug; 30(8):587-92. PubMed ID: 23686524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine agonist withdrawal syndrome (DAWS) in a tertiary Parkinson disease treatment center.
    Patel S; Garcia X; Mohammad ME; Yu XX; Vlastaris K; O'Donnell K; Sutton K; Fernandez HH
    J Neurol Sci; 2017 Aug; 379():308-311. PubMed ID: 28716269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine agonist withdrawal syndrome (DAWS) in a patient with a microprolactinoma.
    Demartini B; Ricciardi L; Ward A; Edwards MJ
    J Neurol Neurosurg Psychiatry; 2014 Apr; 85(4):471. PubMed ID: 24078717
    [No Abstract]   [Full Text] [Related]  

  • 9. Dopamine Agonist Withdrawal Syndrome and Suicidality in Parkinson's Disease.
    Kwan C; Kolivakis T; Huot P
    Can J Neurol Sci; 2023 Sep; 50(5):779-780. PubMed ID: 35801613
    [No Abstract]   [Full Text] [Related]  

  • 10. Dopamine agonist withdrawal syndrome in Parkinson disease.
    Rabinak CA; Nirenberg MJ
    Arch Neurol; 2010 Jan; 67(1):58-63. PubMed ID: 20065130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Impulse control disorders associated with dopaminergic agonists in Parkinson's disease. Case report].
    Gamboa Arango A; Bernal Bernal MT; Duaso Magaña E
    Rev Esp Geriatr Gerontol; 2016; 51(5):304-5. PubMed ID: 27016028
    [No Abstract]   [Full Text] [Related]  

  • 12. Augmentation and impulsivity in restless legs syndrome patients: A complex interaction.
    O'Sullivan SS; Poyares D
    Neurology; 2016 Jul; 87(1):15-6. PubMed ID: 27261094
    [No Abstract]   [Full Text] [Related]  

  • 13. Hypersexuality and compulsive over-eating associated with transdermal dopamine agonist therapy.
    Hinnell C; Hulse N; Martin A; Samuel M
    Parkinsonism Relat Disord; 2011 May; 17(4):295-6. PubMed ID: 21300562
    [No Abstract]   [Full Text] [Related]  

  • 14. Prevention of Dopamine Dysregulation Syndrome in Parkinson's Disease: A Case Report.
    Luchsinger WT; Gambhir N; DeMoss D
    Prim Care Companion CNS Disord; 2018 Apr; 20(2):. PubMed ID: 29701928
    [No Abstract]   [Full Text] [Related]  

  • 15. Partial dopamine agonist-induced pathological gambling and impulse-control deficit on low-dose aripiprazole.
    Peterson E; Forlano R
    Australas Psychiatry; 2017 Dec; 25(6):614-616. PubMed ID: 28696131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of Pathological Gambling and Impulse Control Disorders With Dopamine Agonists: A Retrospective Cohort Study.
    Sodhi M; Etminan M; Carleton B; Samii A
    J Clin Psychopharmacol; 2019; 39(6):675-676. PubMed ID: 31688453
    [No Abstract]   [Full Text] [Related]  

  • 17. Dopamine agonist withdrawal syndrome in Parkinson's disease.
    Solla P; Fasano A; Cannas A; Marrosu F
    J Neurol Sci; 2017 Nov; 382():47-48. PubMed ID: 29111017
    [No Abstract]   [Full Text] [Related]  

  • 18. Addiction-like manifestations and Parkinson's disease: a large single center 9-year experience.
    Limotai N; Oyama G; Go C; Bernal O; Ong T; Moum SJ; Bhidayasiri R; Foote KD; Bowers D; Ward H; Okun MS
    Int J Neurosci; 2012 Mar; 122(3):145-53. PubMed ID: 22023411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of dopamine agonist use with impulse control disorders in Parkinson disease.
    Weintraub D; Siderowf AD; Potenza MN; Goveas J; Morales KH; Duda JE; Moberg PJ; Stern MB
    Arch Neurol; 2006 Jul; 63(7):969-73. PubMed ID: 16831966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transdermal rotigotine in restless legs syndrome: impulse control disorders.
    Prescrire Int; 2014 Oct; 23(153):239. PubMed ID: 25964969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.